An open-label, proof-of-concept study of lirentelimab for antihistamine-resistant chronic spontaneous and inducible urticaria

Sabine Altrichter; Petra Staubach; Malika Pasha; Bhupinder Singh; Alan T. Chang; Jonathan A. Bernstein; Henrik S. Rasmussen; Frank Siebenhaar; Marcus Maurer

doi:10.1016/j.jaci.2021.12.772

An open-label, proof-of-concept study of lirentelimab for antihistamine-resistant chronic spontaneous and inducible urticaria

Sabine Altrichter
, Petra Staubach
, Malika Pasha
, Bhupinder Singh
, Alan T. Chang
, Jonathan A. Bernstein
, Henrik S. Rasmussen
, Frank Siebenhaar
, Marcus Maurer^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	1683-1690.e7
Journal	Journal of Allergy and Clinical Immunology
Volume	149
Issue number	5
DOIs	https://doi.org/10.1016/j.jaci.2021.12.772
Publication status	Published - May 2022
Externally published	Yes

Fields of science

302 Clinical Medicine

Access to Document

10.1016/j.jaci.2021.12.772

Cite this

Altrichter, S., Staubach, P., Pasha, M., Singh, B., Chang, A. T., Bernstein, J. A., Rasmussen, H. S., Siebenhaar, F., & Maurer, M. (2022). An open-label, proof-of-concept study of lirentelimab for antihistamine-resistant chronic spontaneous and inducible urticaria. Journal of Allergy and Clinical Immunology, 149(5), 1683-1690.e7. https://doi.org/10.1016/j.jaci.2021.12.772

@article{195c40dffa53488f9ac02c4461519eb5,

title = "An open-label, proof-of-concept study of lirentelimab for antihistamine-resistant chronic spontaneous and inducible urticaria",

keywords = "AK002, cholinergic urticaria, Siglec-8, symptomatic dermographism",

author = "Sabine Altrichter and Petra Staubach and Malika Pasha and Bhupinder Singh and Chang, \{Alan T.\} and Bernstein, \{Jonathan A.\} and Rasmussen, \{Henrik S.\} and Frank Siebenhaar and Marcus Maurer",

note = "Publisher Copyright: {\textcopyright} 2021 The Authors",

year = "2022",

month = may,

doi = "10.1016/j.jaci.2021.12.772",

language = "English",

volume = "149",

pages = "1683--1690.e7",

journal = "Journal of Allergy and Clinical Immunology",

issn = "0091-6749",

number = "5",

}

Altrichter, S, Staubach, P, Pasha, M, Singh, B, Chang, AT, Bernstein, JA, Rasmussen, HS, Siebenhaar, F & Maurer, M 2022, 'An open-label, proof-of-concept study of lirentelimab for antihistamine-resistant chronic spontaneous and inducible urticaria', Journal of Allergy and Clinical Immunology, vol. 149, no. 5, pp. 1683-1690.e7. https://doi.org/10.1016/j.jaci.2021.12.772

TY - JOUR

T1 - An open-label, proof-of-concept study of lirentelimab for antihistamine-resistant chronic spontaneous and inducible urticaria

AU - Altrichter, Sabine

AU - Staubach, Petra

AU - Pasha, Malika

AU - Singh, Bhupinder

AU - Chang, Alan T.

AU - Bernstein, Jonathan A.

AU - Rasmussen, Henrik S.

AU - Siebenhaar, Frank

AU - Maurer, Marcus

PY - 2022/5

Y1 - 2022/5

KW - AK002

KW - cholinergic urticaria

KW - Siglec-8

KW - symptomatic dermographism

UR - https://www.scopus.com/pages/publications/85122913441

U2 - 10.1016/j.jaci.2021.12.772

DO - 10.1016/j.jaci.2021.12.772

M3 - Article

C2 - 34954198

AN - SCOPUS:85122913441

SN - 0091-6749

VL - 149

SP - 1683-1690.e7

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

IS - 5

ER -

An open-label, proof-of-concept study of lirentelimab for antihistamine-resistant chronic spontaneous and inducible urticaria

Fields of science

Access to Document

Other files and links

Cite this